Washington, September 12, 2017 : Percentage of US college students using marijuana was at the highest level in 2016 since the past three decades, according to a study conducted by University of Michigan researchers.
The national Monitoring the Future follow-up study, funded by the the National Institute on Drug Abuse, showed in 2016, 39 per cent of full-time college students aged 19-22 indicated that they used marijuana at least once in 12 months, and 22 per cent indicated that they used at least once in 30 days, reports Xinhua news agency.
Both of these 2016 percentages were the highest since 1987, and represented a steady increase since 2006, when they were 30 and 17 per cent, respectively.
Daily or near daily use of marijuana-defined as having used 20 or more times in the prior 30 days-was at 4.9 per cent in 2016; this is among the highest levels seen in more than 30 years, though it has not shown any further rise in the past two years.
“These continuing increases in marijuana use, particularly heavy use, among the nation’s college students deserve attention from college personnel as well as students and their parents,” John Schulenberg, the current principal investigator of the Monitoring the Future follow-up study, said on Monday.
“We know from our research and that of others that heavy marijuana use is associated with poor academic performance and non-completion of college.
In 2016, 30 per cent of those aged 19-22 perceived regular use of marijuana as carrying great risk of harm, the lowest level reached since 1980.
These findings come from the long term Monitoring the Future study, which has been tracking substance use of all kinds among American college students for the past 37 years. (IANS)
A drug that curbs delusions in Parkinson’s patients did the same for people with Alzheimer’s disease and other forms of dementia in a study that was stopped early because the benefit seemed clear.
If regulators agree, the drug could become the first treatment specifically for dementia-related psychosis and the first new medicine for Alzheimer’s in nearly two decades. It targets some of the most troubling symptoms that patients and caregivers face — hallucinations that often lead to anxiety, aggression, and physical and verbal abuse.
Results were disclosed Wednesday at a conference in San Diego.
Unmet need for treatment
“This would be a very important advance,” said one independent expert, Dr. Howard Fillit, chief science officer of the Alzheimer’s Drug Discovery Foundation.
Although the field is focused on finding a cure for dementia and preventing future cases, “there is a huge unmet need for better treatment” for those who have it now, said Maria Carrillo, the Alzheimer’s Association’s chief science officer.
The drug is pimavanserin, a daily pill sold as Nuplazid by Acadia Pharmaceuticals Inc. It was approved for Parkinson’s-related psychosis in 2016 and is thought to work by blocking a brain chemical that seems to spur delusions.
About 8 million Americans have dementia, and studies suggest that up to 30% of them develop psychosis.
“It’s terrifying,” said Dr. Jeffrey Cummings of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. “You believe that people might be trying to hurt you. You believe that people are stealing from you. You believe that your spouse is unfaithful to you. Those are the three most common false beliefs.”
How the study worked
He consults for Acadia and helped lead the study, which included about 400 people with dementia and psychosis. All were given a low dose of the drug for three months, and those who seemed to respond or benefit were then split into two groups. Half continued on the drug and the others were given dummy pills for six months or until they had a relapse or worsening of symptoms. Neither the patients nor their doctors knew who was getting what.
Independent monitors stopped the study when they saw that those on dummy pills were more than twice as likely as those on the drug to relapse or worsen — 28% versus nearly 13%.
There were relatively few serious side effects — 5% in the drug group and 4% in the others. Headaches and urinary tract infections were more common among those on the drug. Two deaths occurred, but study leaders said neither was related to the drug.
Carrillo said the study was small, but the drug’s effect seemed large, and it’s not known whether the federal Food and Drug Administration would want more evidence to approve a new use.
Risk of death
Current anti-psychotic medicines have some major drawbacks and are not approved for dementia patients.
“They’re often used off label because we have very few other options,” Fillit said.